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      The somatic and metabolic changes due to menopause can result in numerous symptoms including 
psychological symptoms. This study compares the effectiveness of Gabapentin vs. Fluoxetine in 
treatment of psychological symptoms of menopause. Methods:Eighty menopausal women with history 
of hot flashes and predefined psychological symptoms participated in a cross-over study conducted at the 
Amir-Al-Momenin hospital, Semnan, Iran.  Participants were randomly divided into two groups: A and 
B. The study included two rounds of treatment, each 4 weeks long, separated by a two-week washout 
period. In the first round of treatment, group A was treated with Fluoxetine 20mg/d and group B with 
Gabapentin 300 mg/d. In the second round of treatment, group A received Gabapentin while group B 
received Fluoxetine (cross-over).All participants were asked to fill out the "Green Climacteric Scale" 
questionnaire at the beginning of the study and also following each round of treatment. They were also 
asked to monitor and keep track of the side effects of the medications by filling out another form. There 
was no significant difference between the two groups in age, body mass index, and age at menopause 
(p>0.05). The severity of irritability, fatigue, difficulty in concentrating, difficulty in sleeping, 
nervousness, and palpitation reduced to a significantly greater extent when the participants were treated 
with Gabapentin than when they were treated with Fluoxetine. Side effects (tremor) developed in only 2 
Fluoxetine users and 2 Gabapentin users during the first 4 weeks of treatment. Our findings suggest that 
Gabapentin is more effective in alleviating the psychological symptoms of menopause than Fluoxetine. 
Thus, we recommend Gabapentin 300 mg/d for menopausal women who primarily complain about 
psychological symptoms, or those with contraindication to hormonal therapy. 
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INTRODUCTION  
    The World Health Organization defines 
menopause as the permanent cessation of a 
woman's menstrual cycle due to the termination 
of ovarian follicular activity. If a woman has 
missed her menstrual cycle for at least 12 
consecutive months, and this has not been due to 
pregnancy, breastfeeding, or hormonal disorders, 
then she is considered to be in her menopause 
[1]. Not only a woman's reproductive ability 
ceases with menopause, the quality of her life is 
also affected by the associated physical and 
metabolicchanges. For example, osteoporosis and 
heart conditions are among common 
consequences of menopause [2]. The average age 
of menopause is 51 years old, and despite the 
increase in life expectancy, the menopausal age 
has remained the same [3]. Considering that the 
average life expectancy of American women is 
81 years [4], they spend more than a third of their 
lives in postmenopause [3].  
The main consequence of menopause is reduced 
estrogen level [3] which in turn causes a wide 
range of symptoms in postmenopausal women. 
Psychological symptoms are very common 
during perimenopause and menopause[5,6] and 
can be divided into two main groups: those that 
indicate anxiety and those that are considered as 
signs of depression [7,8]. The risk of depression 
in women is greatest between the ages of 
menarche and menopause [9,10] indicating that 
hormonal changes during this period most likely 
contribute to mood disorders in women [11].  
Sleep disorders are also very common in 
menopausal women. In a study involving a large 
group of French women between the ages of 50 
 




and 64 years, 25% reported sleep disorders [12]. 
From one hundred women who attended a 
menopause clinic, 80% complained from 
insomnia and over 90% complained from 
fatigue[13]. In another study by Kravitz and 
colleagues , 40 to 48% of perimenopausal and 
menopausal women complained from sleeping 
difficulty[14].       
For over 60 years estrogen has been used as a 
hormonal supplement for treatment of 
menopausal symptoms. However, recent studies 
have shown that long term use of estrogen can 
cause numerous side effects including 
cardiovascular events, breast cancer and 
endometrial cancer [15-18]. Furthermore, many 
women are reluctant to use estrogen therapy. In 
addition, hormonal therapy has contraindication 
in women with estrogen-sensitive tumors, 
chronic liver dysfunction, acute thrombosis (with 
or without embolism) and vascular diseases of 
visual nervous system [19]. The aforementioned 
signifies the importance of other approaches, e.g. 
using other hormones and non-hormonal and 
non-medical treatments, for treatment of 
menopausal symptoms. 
Fluoxetine is an antidepressant and belongs to a 
class of medications called Selective Serotonin 
Reuptake Inhibitors (SSRIs). Fluoxetine is used 
for treatment of obsessive-compulsive disorders, 
anxiety and sleep disorders [20,21]. Gabapentin 
is an anti-seizure medication that reduces the 
vasomotor symptoms of menopause [22,23]. 
Gabapentin has also been shown to alleviate a 
sleep disorder unique to women with low serum 
estradiol [24]. 
To the best of our knowledge, the effectiveness 
of Fluoxetine and Gabapentin in treatment of 
psychological symptoms of menopause and their 
potential side effects have not been examined 
yet. Therefore, in this study we examined and 
compared the effectiveness of Fluoxetine (20 
mg/d) and Gabapentin (300 mg/d) in reducing 
the psychological symptoms of menopause. 
Specifically, we measured the participants’ 
scores on irritability and feeling tired or lacking 
in energy as indications of depression, and their 
scores on feeling tense or nervous, heart beating 
quickly or strongly, difficulty in sleeping and 
difficulty in concentrating as indications of 
anxiety. We also monitored and compared the 




MATERIALS AND METHODS 
Participants 
    Menopausal women who visited Amir-al-
Momenin University Hospital in Semnan, Iran, 
complaining from hot flashes were invited to 
participate in this study. Volunteers were 
screened for the following inclusion and 
exclusion criteria: 1. It had been at least a year 
since they had their last monthly menstrual cycle; 
2. They had at least 2 episodes of hot flashes per 
day and primary complaints of the psychological 
symptoms examined in this study; 3. They have 
not been taking any medications for treatment of 
menopausal symptoms during the last month 
prior to the study; 4. They have not been using 
multivitamins or blood thinners such as 
Warfarin; 5. They were not undergoing 
chemotherapy; 6. They were not receiving 
hormone therapy for menopause. Those with 
thyroid disorders, hemophilia, autoimmune 
disorders, diabetes, hypertension, or heart disease 
were also excluded from the study. Eighty 
volunteers who met the aforementioned 
inclusion/exclusion criteria were selected to 
participate in this study. 
Procedure 
    Participants were briefed about menopause 
and its symptoms, prevention and treatment of 
these symptoms, effects of proper nutrition and 
exercise, the purpose of the study, experimental 
procedures and the potential side effects of the 
medications used in the study before signing a 
consent form. All procedures were approved by 
the Research Morality Committee of the Semnan 
Medical Science University.  
Participants were randomly divided into two 
equal groups: A and B. The study included two 
four-week rounds of treatment separated by a 
two-week washout period. In the first round of 
treatment, group A received Fluoxetine 20mg/d 
while group B received Gabapentin 300 mg/d. In 
the second round of treatment, group A received 
Gabapentin and group B received Fluoxetine 
(cross-over). Neither of the groups received any 
medications during the two-week washout 
period.  
At the beginning of the study and also after each 
round of treatment participants were asked to 
answer the questions related to the psychological 
symptoms of menopause in the "Green 
Climacteric Scale" questionnaire[7].  
 
 




They were also asked to fill out a separate form 
created to track the side effects of the two 
medications used in the study, i.e., Gabapentin 
and Fluoxetine.  
Data Analysis 
    Statistical analyses were performed using 
Kolmogorov–Smirnov test, t-test, Mann-
Whitney, paired t-test, and Wilcoxon test. SPSS 
18.0 was used for statistical analyses. For all 
tests, a significance value (p) of less than .05 was 
used to test statistical significance. 
 
RESULTS 
    One participant did not comply with the 
instructions regarding the medication use and 
therefore her data were excluded from the 
analysis. 
There was no significant difference between the 
two groups in age, body mass index and age at 
menopause (P>0.05) (Table 1).  
Table 2 shows the scores of the two groups of 
participants on psychological symptoms based on 
the Greene Climacteric Scale, at the baseline 
(before any medical intervention) and at the end 
of the first and second rounds of treatment. The 
effect of medications on each psychological 
symptom was as follows: 
Irritability 
     In comparison with baseline measures, 
Fluoxetine reduced the severity of irritability in 
group A by 20% (P=0.001) and in group B by 
25% (P=0.002). Gabapentin reduced the 
severity of irritability in group A by 56% 
(P<0.001) and in group B by 76% (P<0.001). 
Changes in the severity of irritability at the end 
of the first round of treatment were significantly 
greater in group B (Gabapentin users) than in 
group A (Fluoxetine users) (P=0.001). 
 Changes in the severity of irritability at the end 
of the second round of treatment were 
significantly greater in group A (Gabapentin 
users) than in group B (Fluoxetine users) 
(P<0.001). 
Fatigue 
   In comparison with baseline measures, 
Fluoxetine reduced the severity of fatigue in 
group A by 30% (P<0.001) and in group B by 
30% (P=0.001). Gabapentin reduced the 
severity of fatigue in group A by 57% 
(P<0.001) and in group B by 77% (P<0.001). 
Changes in the severity of fatigue at the end of 
the first round of treatment were significantly 
greater in group B (Gabapentin users) than in 
group A (Fluoxetine users) (p=0.003). 
Changes in the severity of fatigue at the end of 
the second round of treatment were significantly 
greater in group A (Gabapentin users) than in 
group B (Fluoxetine users) (p=0.029). 
Difficulty in Concentrating 
    In comparison with baseline measures, 
Fluoxetine reduced the difficulty in 
concentrating in group A by 37% (P=0.001) and 
in group B by 25% (P=0.001). Gabapentin 
reduced the difficulty in concentrating in group 
A by 42% (P<0.001) and in group B by 19.5% 
(P=0.003). Changes in difficulty in 
concentrating were not different between the 
two groups, i.e., Fluoxetine and Gabapentin 
users, at the end of the first (P=0.328) and 
second (P=0.155) round of treatment.  
Difficulty in Sleeping  
    Fluoxetine reduced sleeping difficulty in 
group A by 22% (P=0.002) and in group B by 
17% (P=0.172). Gabapentin reduced sleeping 
disorders in group A by 34% (P<0.001) and in 
group B by 77% (P<0.001).  
Changes in the severity of sleeping difficulties 
at the end of the first round of treatment were 
significantly greater in group B (Gabapentin 
users) than in group A(Fluoxetine users) 
(P=0.005). Changes in the severity of sleeping 
difficulties at the end of the second round of 
treatment were significantly greater in group A 
(Gabapentin users) than in group B (Fluoxetine 
users) (P=0.003). 
Table 1. The Mean and Standard Deviation (SD) of Age, Body Mass Index (BMI) and age at menopause for the two groups 
p-value SD Mean Number Group* Characteristics 
 
0.128 
4.4 52.4 39 Group A Age 
 2.4 51.1 40 Group B 
 
0.358 
3.6 27.5 39 Group A BMI 
 3.0 26.8 40 Group B 
 
0.781 
3.1 49.3 39 Group A 
Age at menopause 
2.2 49.5 40 Group B 
* During the first round of treatment (the first 4 weeks), group A received Fluoxetine and group B received Gabapentin. During 
the second round of treatment (the second 4 weeks), group A received Gabapentin and group B received Fluoxetine. 
 
 




Table 2. Mean and Standard Deviation (SD) scores of participants on psychological symptoms based on the Greene Climacteric 
Scale, before any medical intervention and at the end of the first and second rounds of treatment in two groups 
Severity  at the end of 
the second round of 
treatment 
Severity  at the end of 











SD Mean SD Mean SD Mean 
0.76 0.68 0.89 1.23 0.75 1.53 39 Group A 
 
Irritability 
0.75 0.88 0.64 0.28 0.74 1.10 40 Group B 
0.305 < 0.001 0.013 p-value 
0.88 0.50 0.85 0.80 0.95 1.15 39 Group A 
Feeling tired or lacking 
in energy 
0.88 0.70 0.66 0.23 0.82 1.00 40 Group B 
0.170 < 0.001 0.476 p-value 
0.63 0.63 0.69 0.68 0.73 1.08 39 Group A 
Difficulty in 
concentrating 
0.72 0.88 0.88 0.95 0.78 1.18 40 Group B 
0.120 0.178 0.676 p-value 
0.83 0.68 1.03 1.15 1.06 1.48 39 Group A 
Difficulty in sleeping 0.87 0.83 0.53 0.23 0.78 1.00 40 Group B 
0.406 < 0.001 0.034 p-value 
0.90 0.40 1.08 1.15 0.91 1.48 39 Group A 
Feeling tense or nervous 0.88 1.08 0.68 0.48 0.82 1.27 40 Group B 
< 0.001 0.003 0.373 p-value 
0.53 0.23 0.67 0.63 0.61 0.80 39 Group A 
Heart beating quickly 
or strongly 
0.45 0.28 0.58 0.35 0.66 0.85 40 Group B 
0.360 0.043 0.760 p-value 
* During the first round of treatment (the first 4 weeks), group A received Fluoxetine and group B received Gabapentin. During 
the second round of treatment (the second 4 weeks) group A received Gabapentin and group B received Fluoxetine. 
 
Nervousness 
    On average, Fluoxetine reduced the severity of 
nervousness in group A by 22% (P=0.002) and in 
group B by 17% (P=0.013). Gabapentin reduced 
the severity of nervousness in group A by 73% 
(P<0.001) and in group B by 79% (P<0.001). 
Changes in the severity of nervousness at the end 
of the first round of treatment were significantly 
greater in group B (Gabapentin users) than in 
group A (Fluoxetine users) (P=0.004). 
Changes in the severity of nervousness at the end 
of the second round of treatment were 
significantly greater in group A (Gabapentin 
users) than in group B (Fluoxetine users) 
(P<0.001). 
Palpitation 
   On average, Fluoxetine reduced palpitation in 
group A by 21% (P=0.008) and in group B by 
67% (P<0.001). Gabapentin reduced the severity 
of nervousness in group A by 71% (P<0.001) 
and in group B by 59% (P<0.001). 
Changes in the severity of palpitation at the end 
of the first round of treatment was significantly 
greater in group B (Gabapentin users) than group 
A (Fluoxetine users) (P=0.002). Changes in the 
severity of palpitation at the end of the second 
round of treatment were not significantly 
different between the two groups (P=0.897). 
Side Effects 
    In general, most participants did not 
experience any side effects. Two participants 
from each group reported tremor. One participant 
from group A and 2 participants from group B 
reported anorexia.   
 
DISCUSSION 
    The first step in managing depression and 
anxiety in menopausal women is to rule out the 
possibility of other factors unrelated to 
menopause such as thyroid malfunction [25,26], 
preexisting mental illness, significant loss, and 
family history [27]. Different approaches have 
been considered for treatment of depression and 
anxiety due to menopause, including exercise, 
cognitive behavioral therapy and medical 
treatments. Group cognitive behavioral therapy 
has proven effective in treating anxiety in 
menopausal women [28]. Selective Serotonin 
Reuptake Inhibitors (SSRIs) and Serotonin and 
Norepinephrine Reuptake Inhibitors (SNRIs) 
have been used to treat moderate to severe 
depression or anxiety that doesn’t respond to 
non-medical treatments. Previous studies have 
shown that estrogen, alone or in combination 
with progestin, is not effective in treatment of 
severe depression in menopausal women [29,30].  
 
 




There was no difference in the severity of 
depression between menopausal women who 
were treated with estrogen and the control group. 
Furthermore, estrogen did not improve the mood 
of postmenopausal women with mild to moderate 
depression. However, it was beneficial when 
used in combination with an SSRI [31].  We 
found that both Gabapentin and Fluoxetine 
significantly reduce the severity of symptoms of 
depression (i.e., irritability and fatigue), and 
anxiety (i.e., difficulty in concentrating, difficulty 
in sleeping, feeling tense or nervous, and heart 
beating quickly or strongly). The effects of 
Gabapentin and Fluoxetine on difficulty in 
concentrating were not different from each other; 
however, Gabapentin was more effective than 
Fluoxetine in alleviating every other symptom. 
Few studies have examined the effect of 
Gabapentin and Fluoxetine on the psychological 
symptoms of menopause. Depression and sleep 
disorders are among the most common 
symptoms of  menopause and are likely due to 
changes in CNS transmitters, including 
serotonin, norepinephrine, dopamine, and 
endorphins [32]. Serotonin plays a vital role in 
sleep regulation [33]; therefore, changes in 
serotonin level in menopausal women may 
contribute to their sleep disorders. This 
proposition is supported by the fact that 
treatment with an SSRI alleviates sleep disorders 
in menopausal women [34]. While some suggest 
that sleep disorders in menopausal women are 
due to hot flashes [35], results of Freedman's 
study show that such speculation is not always 
true [36].  
SSRIs have been widely studied as potential 
treatments for menopausal mood symptoms. 
SSRIs are considered an appropriate treatment 
for vasomotor symptoms of menopause, given 
the well-documented role of serotonin in 
thermoregulation. Results of short-term clinical 
trials have shown that administration of SSRIs 
may reduce the frequency and severity of hot 
flashes. SSRIs have also been shown to improve 
mood, sleep, anxiety, and quality of life of 
menopausal women and those undergoing 
estrogen-deprivation therapy for breast cancer 
[34, 37, 38].  
 
Combining SSRIs with low-dose hormone 
therapy has also proven to be an effective 
treatment. Results of a small-scale trial have 
shown that a combination of fluvoxamine (50 
mg/d) with low-dose estrogen (0.3125 mg/d) 
was significantly more effective than estrogen 
alone in alleviating depression symptoms 
following oophorectomy [39]. Although it is not 
clear how Fluoxetine works, it does not seem 
that it works through hormonal (e.g. estrogen, 
progesterone, or androgen) pathways. Rather, it 
is speculated that Fluoxetine works by changing 
dopamine, serotonin, or norepinephrine 
pathways [40]. Biglia and colleagues [41] have 
shown that Gabapentin 900 mg/d improves 
sleep quality of menopausal women. Guttuso 
[24] also showed that Gabapentin reduces a type 
of sleep disorder unique to women with low 
serum estradiol. It has been shown that both 
unopposed estrogen therapy (ET) [42,43] and 
combined estrogen–progesterone therapy (EPT) 
[44,45] are effective in treatment of sleep 
disorders in menopausal women [46]. Hormone 
therapy allows examining whether sleep 
disorders during menopause are due to 
hormonal changes or not. In a study by Polo-
Kantola et al., menopausal women who had no 
vasomotor symptoms reported improved sleep 
quality and reduced morning tiredness 
following hormone therapy [43].  
 
CONCLUSION 
   We conclude that Gabapentin is more effective 
than Fluoxetine for treatment of psychological 
symptoms of menopause. Therefore, we 
recommend Gabapentin 300 mg/d for treatment of 
psychological symptoms in postmenopausal 
women who do not respond well to non-medical 
treatments such as exercise and cognitive 
behavioral therapy or those with contraindications 
to hormonal therapy. Future studies should 
investigate the lowest effective dose of 
Gabapentin in order to minimize its side effects. 
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